Rilzabrutinib
Rilzabrutinib (PRN1008) is a potent, selective, and orally bioavailable reversible covalent inhibitor of Bruton's Tyrosine Kinase (BTK) with an IC50 of 1.3 nM. It is a research tool for investigating BTK's role in immunology and oncology, with applications in both in vitro biochemical assays and in vivo disease models.
Product Specifications
CAS Number
1575596-29-0
Product Name Alternative
PRN 1008, PRN1008, PRN-1008, RLK, Rilzabrutinib, TEC, HER4, Inhibitor, ERBB4, ERbB2, ERBB2, EGFR, inhibit, ITK, Bruton tyrosine kinase, BLK, BMX, Btk, BTK
Field of Research
Cardiovascular Research, Signal Transduction
Purity
97.87% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (7.51 mM) ; DMSO:240 mg/mL (360.49 mM)
Smiles
CC (C) (\C=C (/C#N) C (=O) N1CCC[C@H] (C1) n1nc (-c2ccc (Oc3ccccc3) cc2F) c2c (N) ncnc12) N1CCN (CC1) C1COC1
Molecular Formula
C36H40FN9O3
Molecular Weight
665.76
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
030905-ML490 100 µL
CYP1A2 (CYP1A2, Cytochrome P450 1A2, CYPIA2, Cytochrome P (3) 450, Cytochrome P450 4, Cytochrome P450-P3) (MaxLight 490) discontinued
Sign In for Pricing
View Details 